# Raltegravir Switch for Toxicity or Adverse Events

> **NCT00958100** · PHASE2 · COMPLETED · sponsor: **Catholic University of the Sacred Heart** · enrollment: 40 (actual)

## Conditions studied

- HIV/AIDS
- Antiretroviral Therapy
- HIV Infections

## Interventions

- **DRUG:** tenofovir emtricitabine raltegravir
- **DRUG:** Lamivudine Abacavir Raltegravir
- **DRUG:** Abacavir free

## Key facts

- **NCT ID:** NCT00958100
- **Lead sponsor:** Catholic University of the Sacred Heart
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2010-11
- **Final completion:** 2010-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2015-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00958100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00958100, "Raltegravir Switch for Toxicity or Adverse Events". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00958100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*